MediMix on LinkedIn: #medimix #elcc2024 #lungcancer #oncologyinnovation (2025)

Individualizing treatment strategies for patients with stage III non-small cell #lungcancer requires accurate clinical and pathological staging.Explore the evolving treatment journey for patients with NSCLC and earn free #CME here: https://bit.ly/3SWz1XK#MedEd #FOAMed #Oncology

Prof Dr Natalia Valdiviezo Lama shares the post-progression results of the pivotal FLAURA-2 trial. In addition to significantly delaying disease progression, adding chemotherapy to first line osimertinib also significantly improves the time to the first and subsequent line of therapy and delays the progression free survival on the first subsequent line of therapy in patients with EGFR-mutant metastatic NSCLC.Discover these vital insights. 👇 For all ELCC 2024 videos, find the link in the comments!#MediMix #ELCC2024 #LungCancer #OncologyInnovation

1

1 Comment

Your Unique Journey Deserves Personalized Care 🎗️No two breast cancer cases are alike, and at RSNY, we understand the uniqueness of your journey. Dr. Gil Lederman creates personalized treatment plans using advanced radiosurgery, tailored specifically to you. Discover the power of customized care and take the next step in your healing journey at RSNY.org.#RSNY #BreastCancerCare #PersonalizedMedicine #Radiosurgery #CancerTreatment #HealingJourney #BreastCancerAwareness #CustomizedCare #PatientCenteredCare #OncologyCar

Read the blog: https://ow.ly/YCiM50S31ifEVERSANA's Value & Evidence team synthesized the effectiveness of treatments received in the real-world setting after 1L CDK4/6i therapy in patients with HR+/HER2- LABC/mBC. This comprehensive systematic literature review aimed to shed light on the real-world effectiveness of treatments administered after 1L CDK4/6.. Explore their findings and understand the complexities of post-CDK4/6i therapies.#BreastCancer #OncologySarah Kane, Belal Howidi, Bao-Ngoc Nguyen, Joanna Bielecki and Imtiaz A. Samjoo

20

Read the blog: https://ow.ly/YCiM50S31ifEVERSANA's Value & Evidence team synthesized the effectiveness of treatments received in the real-world setting after 1L CDK4/6i therapy in patients with HR+/HER2- LABC/mBC. This comprehensive systematic literature review aimed to shed light on the real-world effectiveness of treatments administered after 1L CDK4/6.. Explore their findings and understand the complexities of post-CDK4/6i therapies.#BreastCancer #OncologySarah Kane, Belal Howidi, Bao-Ngoc Nguyen, Joanna Bielecki and Imtiaz Samjoo

21

🚨Highlights from ESMO 2024! Prof Dr Johan Vansteenkiste, thoracic oncologist at University Hospitals Leuven, shares key insights from two critical trials:- CCTG BR-31: Exploring adjuvant durvalumab in resected NSCLC.- ADRIATIC: Durvalumab as consolidation therapy shows a 10% survival benefit in non-metastatic SCLC.Discover these updates.👇 For all ESMO 2024 videos, find the link in the comments!#MediMix #ESMO2024 #Oncology #LungCancer #NSCLC #SCLC #ClinicalTrials #CancerResearch

1 Comment

🚨 New Tool Alert - CTS5 🚨🔬📊 The Clinical Treatment Score Post-5 Years is a validated, simple clinicopathologic tool to predict late distant recurrence risk in postmenopausal women with ER-positive breast cancer who have finished 5 years of endocrine therapy. 🌟👩⚕️ Use the tool: https://buff.ly/3WKKwn3 #OncoAlert #ONCOtools #BreastCancer

4

Today at #ASCO2024: Our positive Phase 2 clinical and biomarker results with ST101 in GBM were presented during an oral presentation by Dr. Fabio M. Iwamoto, MD, Principal Investigator of the ST101-101 clinical study.The Phase 2 data demonstrates durable responses with ST101 across 3 cohorts of patients with recurrent and newly diagnosed GBM, and supports its continued clinical development as a backbone treatment in combination with standard-of-care and immune-oncology agents.Learn more about these promising results here: https://lnkd.in/g_V2RPzv#ASCO24 #oncology #GBM

48

Striking Results! 🫁 Discovered by the China-based biotech, Akeso, #ivonescimab works differently than Keytruda, which blocks the immune-regulating protein PD-1. Rather, it simultaneously stifles PD-1 and another target implicated in tumor growth, called VEGF. While there are other cancer medicines that inhibit VEGF, obstructing both pathways with a single therapy might have enhanced benefit.💥 Ivonescimabdemonstrates astatistically significant and clinically meaningful improvementin progression-free survival compared to pembrolizumab for patients with PD-L1-positive advanced non-small cell lung cancer!Professor Caicun Zhou, MD, PhD, Chief Physician and Director of the Department of Medical Oncology at Shanghai Pulmonary Hospital, Tongji University School of Medicine, and President-Elect of IASLC, reported the groundbreaking dataof HARMONi-2 at the Presidential Symposium of the #WCLC2024.💥 Ivonescimab demonstrated a clinically meaningful mPFS of 11.14 months vs. 5.82 months with pembrolizumab.💥 Ivonescimab significantly reduced the risk of disease progression or death by 49% vs. pembrolizumab, with a PFS HR of 0.51 (P<0.0001).💥 Ivonescimab significantly improved the ORR to 50.0% vs. 38.5% with pembrolizumab, and the DCR was 89.9% vs.70.5%.💥 PD-L1 high and low expression subgroups: In the PD-L1TPS ≥50% population, ivonescimab achieved a PFS HR of 0.46 vs. pembrolizumab. In the PD-L1 TPS 1-49% population, the PFS HR was 0.54.💥 Squamous and non-squamous histologies subgroups: In squamous NSCLC, ivonescimab showed a PFS HR of 0.48; in non-squamous NSCLC, the PFS HR was 0.54.💥 Refractory subgroups:Ivonescimab showed significantly better clinical benefits compared to pembrolizumab in refractory patient populations, including those with liver metastases and brain metastases.🌟 WOW! Possible practice-changing results in #NSCLC! What an honor to live during these times where our research in lung cancer has come so far, and to see patients benefiting from that research in real time, in our families, in our friendships, and for so many whom we love enduring the struggle of beating cancer.

1

Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients withPD-L1 Positive Advanced NSCLC in China Full Press Release Here: https://lnkd.in/gAvUNM_N#SummitTherapeutics #oncology #WCLC24 #IASLC #Ivonescimab

392

9 Comments